Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.

Fiche publication

Date publication

septembre 2018

Journal

Atherosclerosis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel , Pr VERGES Bruno

Tous les auteurs :
Wargny M, Ducluzeau PH, Petit JM, Le May C, Smati S, Arnaud L, Pichelin M, Bouillet B, Lannes A, Blanchet O, Lefebvre P, Francque S, Van Gaal L, Staels B, Vergès B, Boursier J, Cariou B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30261472

Résumé

Some studies suggested that proprotein convertase subtilisin kexin type 9 (PCSK9) is linked to liver steatosis severity and non-alcoholic steatohepatitis (NASH). We aimed to assess whether circulating PCSK9 levels are associated with either liver fat content (LFC) or histological markers of NASH in high-risk patients.